The study says the Oxford AstraZeneca vaccine, a version of which is manufactured as Covishield
in India, might offer protection lasting a lifetime.
It means the body can continue making these vital cells long after the antibodies have waned – as
possibly for the rest of your life.
Scientists from Oxford and Switzerland, writing in journal Nature, say T-cell protection is a “key
feature” of adenovirus vaccines like the Oxford and J&J jabs.
Researcher Prof Burkhard Ludewig, of Cantonal Hospital in Switzerland, said: “The T-cells that come
from these cellular training camps appear to have a very high level of ‘fitness’.
“Adenoviruses have co-evolved with humans over a very long time, and learned a lot about the
human immune system in the process.
“Viruses are always the best teachers, and here they have taught us an important lesson about how
best to boost killer T-cell responses.
“Hopefully we can put this to good use in designing new vaccines targeting other diseases like TB,
HIV, hepatitis C and cancer.”
The researchers found adenoviruses are able to get into long-lived tissue cells, known as fibroblastic
reticular cells, which act as “training grounds” for T-cells.
Previous studies have shown the Oxford jab is more effective at generating T-cells than mRNA
vaccines like the Pfizer and Moderna ones.
T-cell levels are difficult to measure, but the new study gives hope that they may last a lifetime.
Prof Paul Klenerman, of Oxford’s Nuffield Department of Medicine, said: “Millions of people have
received adenovirus vaccines around the world.
The ultimate goal with these vaccines is the induction of long-term immune system protection using
both antibodies and T-cells.
“This research helps us to understand more on the process of vaccination, and why the effects on
killer T-cells are so prolonged.”
L’Afrique enregistre la plus forte croissance du nombre de développeurs de logiciels dans le monde (BCG)
Alors que les technologies numériques transforment de plus en plus les économies